Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Keratoconjunctivitis Sicca: early-phase trial registry
A small indexed set (11 trials) with no open enrollment listed right now.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · none currently recruiting · #1,577 of 28,707 conditions by registered trial count
Keratoconjunctivitis Sicca: 11 US clinical trials tracked, none currently recruiting.
Keratoconjunctivitis Sicca is the subject of 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Oculeve, running 1 of these trials.
Enrollment posture brief
Registry condition keratoconjunctivitis-sicca
OPEN 0 | RECR 0% | LATE 2 | EARLY 6 | RANK #1577 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Keratoconjunctivitis Sicca has no open enrollment in this registry pull (11 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Keratoconjunctivitis Sicca on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Keratoconjunctivitis Sicca is recruiting below its size-band peers.
0 of 11 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Keratoconjunctivitis Sicca trials is spread across many organizations.
Oculeve accounts for 1 of 11 trials (9.1%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Keratoconjunctivitis Sicca enrolment sits around 55 participants.
Median target enrolment is 55 among the 11 trials that report a genuine target (sentinel values excluded). 6 of those (54.5%) plan for fewer than 100 participants.
-
Keratoconjunctivitis Sicca research is mostly interventional.
10 interventional and 1 observational studies make up this index (90.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Novartis
NCT00128245
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
Mimetogen Pharmaceuticals USA
NCT02665234
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
TearLab Corporation
NCT00848198
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
Glaukos Corporation
NCT05119920
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
Kubota Vision
NCT01027013
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
Oculeve
NCT02798289
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
Lux Biosciences
NCT00851734
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
National Eye Institute (NEI)
NCT00001731
Dry Eye Assessment and Management: Feasibility Study
Asbell, Penny, M.D.
NCT01102257
Effects of Dry Eye Treatments on the Ocular Surface
Baylor College of Medicine
NCT01797822
Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points
University of Texas Southwestern Medical Center
NCT00345241
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Keratoconjunctivitis Sicca records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Keratoconjunctivitis Sicca trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Keratoconjunctivitis Sicca page
11 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Keratoconjunctivitis Sicca trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Oculeve sponsors the most Keratoconjunctivitis Sicca trials on record, review their full trial history before evaluating a specific study. See Oculeve's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Keratoconjunctivitis Sicca condition card totals 11 registered trials; most-linked intervention Oculeve Intranasal Neurostimulator; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.